Quizartinib Uses, Dosage, Side Effects and more
Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.
In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).
| Attribute | Details |
|---|---|
| Trade Name | Quizartinib |
| Generic | Quizartinib |
| Quizartinib Other Names | Quizartinib, Quizartinibum |
| Type | |
| Formula | C29H32N6O4S |
| Weight | Average: 560.67 Monoisotopic: 560.220574708 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Quizartinib works
Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.
